We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Michelle
Oakford
Dr
Medical Information and
Product Information Enquiry
+44 (0)800 731 8450 / 10494 567 444
medinfo@its.jnj.com
Plaque psoriasis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Plaque psoriasis is a skin disease that causes red, scaly, and sometimes painful and itchy patches on the skin.
Drugs that prevent interleukin IL-23* from binding to its receptor** may be an effective way to disease control. JNJ-77242113 is designed to target IL-23 receptor and block IL-23 from binding to it.
(*A specific type of protein involved in inflammation.)
(**A protein that binds to specific molecule.)
The purpose of this study is to see how effective JNJ-77242113 is in participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Participants will receive JNJ-77242113 or placebo in a 2:1 ratio which means in every 2 participants who receive JNJ-77242113, 1 will receive placebo. JNJ-77242113 will be administered in all treatment groups (JNJ-77242113, placebo). This is a double-blind study, which means participant, caregiver, and study doctor will not know whether the participants are receiving JNJ-77242113 or placebo.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular) 2. Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantar pustulosis of the palmoplantar area (if hf-PGA >=3 at baseline) 3. Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)4. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, haematologic, rheumatologic, psychiatric, or metabolic disturbances 5. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Michelle
Oakford
Dr
Medical Information and
Product Information Enquiry
+44 (0)800 731 8450 / 10494 567 444
medinfo@its.jnj.com
The study is sponsored by Janssen-Cilag International NV and funded by Janssen Research and Development.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 57585
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
